Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-head randomized trial of molnupiravir versus Paxlovid in high-risk adults with mild or moderate COVID-19
ChiCTR2200060010Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Paxlovid (2 arms). Primary endpoint: Days to viral nucleic acid negative conversion. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
molnupiravirNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060010.